These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35446149)

  • 1. Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis.
    Moccia M; Loperto I; Santoni L; Masera S; Affinito G; Carotenuto A; Lanzillo R; Triassi M; Morra VB; Palladino R
    Neurodegener Dis Manag; 2022 Jun; 12(3):109-116. PubMed ID: 35446149
    [No Abstract]   [Full Text] [Related]  

  • 2. No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS.
    Ryerson LZ; Naismith RT; Krupp LB; Charvet LE; Liao S; Fisher E; de Moor C; Williams JR; Campbell N
    Mult Scler Relat Disord; 2022 Feb; 58():103480. PubMed ID: 35051898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended interval dosing of natalizumab in multiple sclerosis.
    Zhovtis Ryerson L; Frohman TC; Foley J; Kister I; Weinstock-Guttman B; Tornatore C; Pandey K; Donnelly S; Pawate S; Bomprezzi R; Smith D; Kolb C; Qureshi S; Okuda D; Kalina J; Rimler Z; Green R; Monson N; Hoyt T; Bradshaw M; Fallon J; Chamot E; Bucello M; Beh S; Cutter G; Major E; Herbert J; Frohman EM
    J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):885-9. PubMed ID: 26917698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients.
    Valentino P; Malucchi S; Martire S; Bava CI; Capobianco MA; Bertolotto A
    Mult Scler Relat Disord; 2022 Nov; 67():104176. PubMed ID: 36126541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive multifocal leukoencephalopathy with natalizumab extended or standard interval dosing in the United States and the rest of the world.
    Dsilva L; McCarthy K; Lyons J; Cabigas B; Campbell N; Kong G; Adams B; Kuhelj R; Singhal P; Smirnakis K
    Expert Opin Drug Saf; 2023; 22(10):995-1002. PubMed ID: 37272350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
    Toorop AA; van Lierop ZY; Gelissen LM; Hoitsma E; Zeinstra EM; van Rooij LC; van Munster CE; Vennegoor A; Mostert JP; Wokke BH; Kalkers NF; Hoogervorst EL; van Eijk JJ; Roosendaal CM; Kragt JJ; Eurelings M; van Genugten J; Nielsen J; Sinnige L; Kloosterziel ME; Arnoldus EP; van Dijk GW; Bouvy WH; Wessels MH; Boonkamp L; Strijbis EM; van Oosten BW; De Jong BA; Lissenberg-Witte BI; Barkhof F; Moraal B; Teunissen CE; Rispens T; Uitdehaag BM; Killestein J; van Kempen ZL
    J Neurol Neurosurg Psychiatry; 2024 Apr; 95(5):392-400. PubMed ID: 37963723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.
    Ryerson LZ; Foley J; Chang I; Kister I; Cutter G; Metzger RR; Goldberg JD; Li X; Riddle E; Smirnakis K; Kasliwal R; Ren Z; Hotermans C; Ho PR; Campbell N
    Neurology; 2019 Oct; 93(15):e1452-e1462. PubMed ID: 31515290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis.
    Toorop AA; Noteboom S; Steenwijk MD; Gravendeel JW; Jasperse B; Barkhof F; Strijbis EM; Rispens T; Schoonheim MM; van Kempen ZL; Killestein J
    Mult Scler; 2024 Feb; 30(2):266-271. PubMed ID: 38235514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis.
    Rabea EM; Belal MM; Hafez AH; Elbanna AH; Khalifa MA; Nourelden AZ; Mahmoud NH; Zaazouee MS
    Acta Neurol Belg; 2024 Apr; 124(2):407-417. PubMed ID: 38457005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of natalizumab extended interval dosing.
    Yamout BI; Sahraian MA; Ayoubi NE; Tamim H; Nicolas J; Khoury SJ; Zeineddine MM
    Mult Scler Relat Disord; 2018 Aug; 24():113-116. PubMed ID: 29982107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study.
    De Mercanti SF; Signori A; Cordioli C; Signoriello E; Lus G; Bonavita S; Abbadessa G; Lavorgna L; Maniscalco GT; Curti E; Lorefice L; Cocco E; Nociti V; Mirabella M; Baroncini D; Mataluni G; Landi D; Petruzzo M; Lanzillo R; Gandoglia I; Laroni A; Frangiamore R; Sartori A; Cavalla P; Costantini G; Capra R; Sormani MP; Clerico M
    J Neurol Sci; 2021 May; 424():117385. PubMed ID: 33770708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study.
    Riancho J; Setien S; Sánchez de la Torre JR; Torres-Barquin M; Misiego M; Pérez JL; Castillo-Triviño T; Menéndez-García C; Delgado-Alvarado M
    Front Immunol; 2021; 12():614715. PubMed ID: 33841397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
    Foley JF; Defer G; Ryerson LZ; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Smirnakis K; Xiao S; Kong G; Kuhelj R; Campbell N;
    Lancet Neurol; 2022 Jul; 21(7):608-619. PubMed ID: 35483387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing.
    Foley JF; Goelz S; Hoyt T; Christensen A; Metzger RR
    Mult Scler Relat Disord; 2019 Jun; 31():65-71. PubMed ID: 30939392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natalizumab extended interval dosing: what about wearing-off effect?
    Bernardes C; Fernandes C; Cunha C; Nunes C; Macário C; Sousa L; Batista S; Correia I
    J Neurol Sci; 2024 Mar; 458():122930. PubMed ID: 38368641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study.
    Santiago-Setien P; Barquín-Rego C; Hernández-Martínez P; Ezquerra-Marigomez M; Torres-Barquin M; Menéndez-Garcia C; Uriarte F; Jiménez-López Y; Misiego M; Sánchez de la Torre JR; Setien S; Delgado-Alvarado M; Riancho J
    Front Immunol; 2023; 14():1086028. PubMed ID: 36817456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.
    Ryerson LZ; Foley JF; Defer G; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Sinks S; Kuhelj R; Bodhinathan K; Lasky T
    Mult Scler Relat Disord; 2023 Apr; 72():104561. PubMed ID: 36931078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
    Mancinelli CR; Scarpazza C; Cordioli C; De Rossi N; Rasia S; Turrini MV; Capra R
    Mult Scler; 2021 Apr; 27(5):790-794. PubMed ID: 32749910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
    Clerico M; De Mercanti SF; Signori A; Iudicello M; Cordioli C; Signoriello E; Lus G; Bonavita S; Lavorgna L; Maniscalco GT; Curti E; Lorefice L; Cocco E; Nociti V; Mirabella M; Baroncini D; Mataluni G; Landi D; Petruzzo M; Lanzillo R; Gandoglia I; Laroni A; Frangiamore R; Sartori A; Cavalla P; Costantini G; Sormani MP; Capra R
    Neurotherapeutics; 2020 Jan; 17(1):200-207. PubMed ID: 31452081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience.
    Nasello M; Zancan V; Rinaldi V; Marrone A; Reniè R; Diamant S; Marconi M; Le Mura L; Salvetti M; Buscarinu MC; Bellucci G
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.